Prognostic role of angiotensin-II receptor type 1 and endothelin-1 receptor type A agonistic autoantibodies in patients with acute myocardial infarction

Prognostic role of angiotensin-II receptor type 1 and endothelin-1 receptor type A agonistic autoantibodies in patients with acute myocardial infarction

BackgroundFunctional autoantibodies against angiotensin II type 1 (AT1R-AAs) and endothelin-1 type A (ETAR-AAs) receptors are associated with microvascular obstruction and myocardial remodeling after ST-elevation myocardial infarction (STEMI). However, their role in the long-term prognosis after STE...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesco Tona, Giovanni Civieri, Marta Vadori, Giulia Masiero, Laura Iop, Martina Perazzolo Marra, Annagrazia Cecere, Marika Martini, Donatella Tansella, Giacomo Bernava, Benedetta Schiavon, Loira Leoni, Emanuele Cozzi, Sabino Iliceto
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
autoimmunity
no-reflow
coronary microcirculation
G protein coupled receptors
acute coronary syndrome
adverse prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1515693/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundFunctional autoantibodies against angiotensin II type 1 (AT1R-AAs) and endothelin-1 type A (ETAR-AAs) receptors are associated with microvascular obstruction and myocardial remodeling after ST-elevation myocardial infarction (STEMI). However, their role in the long-term prognosis after STEMI has not been investigated.MethodsThis is a prospective observational study enrolling STEMI patients undergoing early primary PCI. The incidence of major adverse cardiovascular events (MACE) was investigated during the follow-up. Autoantibody seropositivity was defined as a level >10 U/ml.Results200 STEMI patients (89% male, median age 61 years) were enrolled. 110 (55%) were seronegative for both autoantibodies, 44 (22%) were seropositive for one autoantibody, and 46 (23%) were seropositive for both autoantibodies. Over a median follow-up of 1.2 years, the incidence of MACE was higher in patients with double (31%) and single (25%) seropositivity than in seronegative patients (13%, p = 0.02 among groups). Double seropositivity was independently associated with higher risk of MACE (HR 2.386, 95% CI 1.471–3.864, p < 0.001).ConclusionAT1R-AAs and ETAR-AAs are associated with an increased risk of MACE after STEMI. Assessment of autoantibody levels paves the way for future therapies targeting specific molecular pathways associated with poor prognosis after an acute coronary event.
ISSN:2297-055X

Similar Items